Clinical trials: Primary Immune Thrombocytopenia
Autoimmune Cytopenia, Immune Thrombocytopenia (ITP)
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia
- Conditions
- Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
- Trial name
- NCT07175493
- Testing
- CM336 Injection
- Where
- 3 sites in China
- Volunteers
- 158 people
- Sponsor
- Keymed Biosciences Co.Ltd
Primary Immune Thrombocytopenia (ITP)
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.
- Trial name
- ADVANCE2 (NCT04274452)
- Testing
- efgartigimod
- Sponsor
- argenx
Immune Thrombocytopenic Purpura
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
- Trial name
- ITP (NCT02273960)
- Testing
- BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV
- Where
- 20 sites in United States, Australia and 6 more
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Thrombocytopenic Purpura
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
The purpose of this study is to investigate the efficacy, safety and tolerability of eltrombopag in children with previously treated chronic immune thrombocytopenia who are between 1 and 17 years of age. This is a 2 part study.
- Trial name
- PETIT2 (NCT01520909)
- Testing
- Eltrombopag
- Where
- 51 sites in United States, Argentina and 11 more
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
The purpose of this study is to evaluate changes in bone marrow morphology (structure) after long-term exposure to romiplostim.
- Trial name
- NCT00907478
- Testing
- romiplostim
- Volunteers
- 169 people
- Sponsor
- Amgen
Primary Immune Thrombocytopenia (ITP)
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.
- Trial name
- NCT05885555
- Testing
- Ianalumab
- Where
- 24 sites in United States, Argentina and 11 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Autoimmune Thrombocytopenia
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
This is a single-arm, open-label，phase I clinical study to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection in treatment of refractory systemic lupus erythematosus-related immune thrombocytopenia.
- Trial name
- NCT06826430
- Testing
- Inaticabtagene autoleucel Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Juventas Cell Therapy Ltd.
Thrombocytopenia
Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.
- Trial name
- NCT02718716
- Testing
- UCB7665
- Where
- 29 sites in Australia, Bulgaria and 9 more
- Volunteers
- 66 people
- Sponsor
- UCB Biopharma SRL
Immune Thrombocytopenia
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)
The main purpose of this study is to assess the efficacy and safety of LIV-GAMMA SN Inj. in adult subjects with ITP. The primary objective of this study is to determine the responder rate.
- Trial name
- NCT03164915
- Testing
- LIV-GAMMA SN Inj.
- Where
- 6 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- SK Plasma Co., Ltd.
Immune Thrombocytopenia (ITP)
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur.
- Trial name
- NCT06721013
- Testing
- Pirtobrutinib
- Where
- 43 sites in United States, China and 8 more
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Immune Thrombocytopenia
Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
Evaluate the efficacy, safety, and PK of avatrombopag given for 26 weeks in Japanese adults with chronic immune thrombocytopenia (ITP).
- Trial name
- NCT05369208
- Testing
- Avatrombopag Oral Tablet
- Where
- 19 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Sobi, Inc.
Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP)
Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions
This is an open-label, randomized, crossover Phase 1 study to evaluate the bioequivalence, pharmacokinetics, and safety of two oral SKI-O-703 drugs (test and reference) in healthy adults under fed conditions.
- Conditions
- Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP), Rheumatoid Arthritis (RA)
- Trial name
- NCT07675226
- Testing
- SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Oscotec Inc.
Primary Immune Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP.
- Trial name
- ADVANCE SC (NCT04687072)
- Testing
- Efgartigimod PH20 SC
- Where
- 200 sites in United States, Argentina and 30 more
- Volunteers
- 207 people
- Sponsor
- argenx
Immune Thrombocytopenia
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
The objective is to evaluate the efficacy and safety of romiplostim for injection in adlut subjects with persistent or chronic primary immune thrombocytopenia (ITP).
- Trial name
- NCT02868099
- Testing
- Romiplostim
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.
Primary Immune Thrombocytopenia
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study. The primary objective is to evaluate the safety and efficacy of SG301 SC Injection in participants with ITP, while the secondary…
- Trial name
- NCT07710248
- Testing
- low dose group, high dose group
- Where
- 22 sites in China
- Volunteers
- 60 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06371417
- Testing
- RAY121
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Immune Thrombocytopenia (ITP)
A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206.
- Trial name
- NCT06853444
- Testing
- ESG206
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
ITP, Immune Thrombocytopenia
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult patients who have an insufficient…
- Trial name
- NCT04904276
- Testing
- Fostamatinib
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Rigel Pharmaceuticals
Lupus Nephritis (LN), Immune Thrombocytopenia (ITP)
A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
This study evaluates the safety and efficacy of YTS109 cells in adults with refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus-Immune Thrombocytopenia (SLE-ITP).
- Trial name
- NCT06943937
- Testing
- YTS109 cell injection
- Where
- China
- Volunteers
- 2 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Drug Effect, Safety Issues
Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia
The goal of this clinical trial is to demonstrate equivalent efficacy and comparable safety of the drug GP40141 (GEROPHARM, Russia) in comparison with the drug Nplate® (Amgen, the Netherlands). the main questions are 1.
- Conditions
- Drug Effect, Safety Issues, Immunogenicity
- Trial name
- NCT06497036
- Testing
- GP404141, Nplate
- Where
- 6 sites in Russia
- Volunteers
- 160 people
- Sponsor
- Geropharm